Figure 3.
Anti-PD-1/PD-L1 inhibitors are approved by FDA for the treatment of lung cancer. The PD-1 inhibitors such as nivolumab, pembrolizumab, and cemiplimab and the PD-L1 inhibitors such as atezolizumab and durvalumab were illustrated in the panel. PD-1, programmed death 1; PD-L1, programmed death 1 ligand.